Navigation Links
New Research Uses Ethical Stem Cells to Create Liver Buds and Artificial Bones
Date:7/31/2013

NEW YORK, July 31, 2013 /PRNewswire/ -- This month, scientific journals have reported on two more studies that highlight how stem cells found in babies' umbilical cord blood and cord tissue represent the future of medical treatments for serious diseases and injuries. Nature, The International Weekly Journal of Science, reported that Japanese scientists have successfully engineered rudimentary human livers, or "liver buds", using three types of stem cells. And, ScienceDaily reported that Spanish scientists have patented a biomaterial that helps create artificial bones using umbilical cord blood stem cells. These developments are among many in an industry that is pioneering stem cell-based therapies for many life threatening and debilitating diseases and injuries, including some that children may be more susceptible to as a result of family medical history.

In Japan, the researchers used human induced pluripotent stem cells (iPSCs), endothelial cells, and mesenchymal stem cells (MSCs) to create liver buds. When they implanted the liver buds in mice, the liver buds performed some functions of a liver, including protein production and drug metabolism. iPSCs are a type of pluripotent stem cell artificially derived from a non-pluripotent cell. MSCs can be found in babies' umbilical cord tissue and placenta tissue and can be collected and preserved immediately after a baby is born.

In Spain, the researchers used umbilical cord blood stem cells to create a biomaterial that helped develop bone tissue. The next step in their research will be to implant the bone tissue in laboratory animals and determine whether it can successfully regenerate bones. If successful, this kind of medical therapy would be helpful for people who have suffered bone trauma due to disease or accidents. Umbilical cord blood stem cells are found in the umbilical cord and placenta immediately after a baby is born.

Research into uses of stem cells from cord blood is growing at a rapid pace. Earlier this year, BioInformant Worldwide, a research company focused on the stem cell industry, reported that there were 78 ongoing clinical trials in 2008 compared to 191 in 2012; this represents a 144% increase in clinical trials for cord blood research in just 5 years. Currently, over 80 diseases have been treated with umbilical cord blood stem cells.

"We believe that preserving a baby's stem cells creates a unique the opportunity for that child to have access not only to today's cutting-edge medical therapies, but also to medical therapies that will be developed in the future," said Martin Smithmyer, CEO of Americord Registry. "These newest reports of advances in stem cell research give us even greater reason to be extremely optimistic about the future of stem cell therapies."

About Americord
Americord is a leader in the advancement of umbilical cord bloodcord tissue and placenta tissue banking. Americord collects, processes, and stores newborn stem cells from umbilical cord blood for future medical or therapeutic use, including the treatment of more than 80 blood diseases such as sickle cell anemia and leukemia. Founded in 2008, Americord is registered with the FDA and operates in all 50 states. The company's laboratory is CLIA Certified, accredited by the AABB and complies with all federal and state guidelines and applicable licenses. Americord is headquartered in New York, NY. You may visit Americord's website at cordadvantage.com for more information. You may also find Americord on Facebook and follow the company on Twitter.

 Contact: Andrew FlookAmericord Registry866-503-6005andrew.flook@cordadvantage.com


'/>"/>
SOURCE Americord
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Wolters Kluwer Research Now Available via Bloomberg Tradebook
2. ACORN Research, LLC Announces Partnership with AdeptBio, LLC
3. New England Biolabs Introduces Polbase, an Information Repository of Scientific Data for Polymerase Researchers
4. Researching graphene nanoelectronics for a post-silicon world
5. In new quantum-dot LED design, researchers turn troublesome molecules to their advantage
6. BBVA Foundation Unites the Efforts of Massachusetts General Hospital and Barcelonas Vall dHebron Hospital in Biomarker Research for Personalized Cancer Therapies
7. New research points to benefits of innovative cobas® HPV test for primary screening as Englands cervical cancer screening programme includes the test in current HPV "triage" rollout
8. Multidisciplinary team of researchers develop world’s lightest material
9. K computer research results awarded ACM Gordon Bell Prize
10. ResearchMoz: Ophthalmic Devices Market to 2017 - Glaucoma and Cataract Surgery Devices, Minimally Invasive Procedures in Ophthalmic Surgery to Drive the Ophthalmic Surgery Market
11. Researchers shrink tumors and minimize side effects using tumor-homing peptide to deliver treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... NEW YORK , Feb. 23, ... , a leading digital health company, and ... of telemedicine and remote patient monitoring, announce they ... reimbursements.  DN Telehealth maximizes collaboration ... real-time, extending consultations beyond a physical clinical setting ...
(Date:2/23/2017)... ... February 23, 2017 , ... BellBrook ... portfolio to include an array of biochemical analyses critical for Lead Discovery. ... their hit-to-lead and SAR programs, including inhibitor potency and selectivity, mechanism of action, ...
(Date:2/23/2017)... , Feb. 23, 2017  MIODx announced ... for two key immunotherapy technologies from the University ... provides a method to monitor a patient for ... PD-L1 and CTLA-4.  The second license extends the ... patient is likely to have an immune-related adverse ...
(Date:2/23/2017)... Feb. 23, 2017  Seattle,s upscale Capitol Hill neighborhood, with its ... place for a head lice treatment salon to set up ... Tuscan restaurant and a French bistro on E Madison Ave, ... aren,t just any old lice clinic, we pride ourselves on ... and release some of the stigma associated with lice. Everyone ...
Breaking Biology Technology:
(Date:2/24/2017)... Spain , Feb. 24, 2017  EyeLock LLC, a ... demonstrate its elite iris biometric solution on the ... X16 LTE at Mobile World Congress 2017 ... Qualcomm,s Booth in Hall 3, Stand 3E10. ... the Qualcomm Haven™ security platform—a combination of ...
(Date:2/21/2017)... 21, 2017 Der weltweite Biobanking-Sektor ... Nach einem Gespräch mit mehr als 50 Vertretern aus verschiedenen ... überwinden gilt, um diese Prognose zu realisieren. ... Zu ... der finanziellen Mittel für die Biobank, die Implementierung Zeit ...
(Date:2/13/2017)... Feb. 13, 2017  RSA Conference -- RSA, a ... is designed to enhance fraud detection and investigation ... the RSA Fraud & Risk Intelligence Suite. The ... leverage additional insights from internal and external sources ... protect their customers from targeted cybercrime attacks. ...
Breaking Biology News(10 mins):